ClinicalTrials.gg
CompletedNCT00029835RIO-LipidsUpdated Apr 20, 2009

Obese Patients With Untreated Dyslipidemias

A Phase 3 interventional study of Rimonabant (SR141716) in Obesity and Dyslipidemia, sponsored by Sanofi. Completed at 35 sites in 8 countries. Open to participants aged 18 Years to 70 Years. Per ClinicalTrials.gov, last updated 2009-04-20.

Sponsored by Sanofi · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
1,033
Allocation
Randomized
Ages
18 Years to 70 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 21 studies testing rimonabant in Obesity — none open to participants now, none under way, none of them phase 3. Rimonabant · Obesity.

Enrollment
6th of 21
1,033 · median 643
Started
2001
with 3 others
Phase 3
18 of 21
none open now
Registered
1st of 21
by date
Lead sponsor
19 of 21
Sanofi

Among the 21 studies testing rimonabant in Obesity, this one is the 6th largest by enrollment, is one of 4 that started in 2001, is one of 18 in phase 3, and was the 1st registered.

Obesity

11,543 studies on the registry are indexed under Obesity; 2,047 are open to participants now.

Browse Obesity studies →

Open to participants now

None of the 21 studies testing rimonabant in Obesity is open now. The open studies under Obesity, anywhere →

About rimonabant

Rimonabant: first EMA approval 2006. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 1,342 Obesity studies recruiting now, 377 (28%) set no upper age limit and 861 (64%) stop at 75 or younger; 168 take children under 18; 489 take healthy volunteers.

This study: 18 Years to 70 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Download CSVNarrow it in search →With an account: the 21 studies testing rimonabant in Obesity as a file.
02

Study summary

To assess the effect on weight loss and weight maintenance over a period of one year when prescribed with a hypocaloric diet in obese patients with untreated dyslipidemia

03

Conditions studied

  • Obesity
  • Dyslipidemia

Keywords

  • Obesity
04

Who can participate

Ages eligible
18 Years to 70 Years
Sexes eligible
All
Accepts healthy volunteers
No

Eligibility criteria

  • must be greater than 27 and less than 40
  • Patients with untreated dyslipidemia
  • Stable weight (variation of less than 5 kg within 3 months prior to screening visit)
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
1,033 participants (actual)

Interventions

06

What researchers measure

Primary outcomes

  1. Change from baseline in body weight at 1 year.

Secondary outcomes

  1. Metabolic parameters

07

Study locations

35 sites
  • Clinic of Physicians and Surgeons, LTD
    Mesa, Arizona 85201, United States
  • Arizona Clinical Research Center, Inc.
    Tucson, Arizona 85712, United States
  • Irvine Center for Clinical Research (ICCR)
    Irvine, California 92618, United States
  • Los Angeles Clinical Trials
    Los Angeles, California 90064, United States
  • Apexute
    Santa Ana, California 92705, United States
  • Clinical Research of South Florida
    Coral Gables, Florida 33134, United States
  • Radiant Research
    Stuart, Florida 34996, United States
  • nTouch Research
    Peoria, Illinois 61602, United States
  • nTouch Research
    South Bend, Indiana 46601, United States
  • Bluegrass Clinical Research, Inc.
    Louisville, Kentucky 40291, United States
  • Johns Hopkins Women's Research Core
    Lutherville, Maryland 21093, United States
  • Baystate Medical Center
    Springfield, Massachusetts 01199, United States
  • Twin Cities Clinical Research
    Arden Hills, Minnesota 55126, United States
  • Radiant Research
    Edina, Minnesota 55435, United States
  • Women's Clinic of Lincoln, PC
    Lincoln, Nebraska 68510, United States
  • New Mexico Clinical Research & Osteoporosis Center, Inc.
    Albuquerque, New Mexico 87106, United States
  • Clinical Research Services
    Bismarck, North Dakota 58501, United States
  • University of Cincinnati College of Medicine
    Cincinnati, Ohio 45267-0559, United States
  • Altoona Center for Clinical Research
    Duncansville, Pennsylvania 16635, United States
  • Clinical Research Division
    Newtown, Pennsylvania 18940, United States
  • Clinical Research Center of Reading, LLC
    West Reading, Pennsylvania 19611-1124, United States
  • Medical University of South Carolina, Division of Clinical Pharmacology
    Charleston, South Carolina 29425, United States
  • Nashville Medical Research Institute
    Nashville, Tennessee 37205, United States
  • Radiant Research
    Salt Lake City, Utah 84111, United States
  • Clinical Research Center of Northern Virginia
    Falls Church, Virginia 22044, United States
  • Hunter Holmes McGuire Medical Center Research Service (151)
    Richmond, Virginia 23249, United States
  • Vancouver Medical Weight Loss Clinic
    Vancouver, Washington 98685, United States
  • Addiction & Psychiatric Medicine Research
    Morgantown, West Virginia 26506-9300, United States
  • Sanofi-aventis Administrative Office
    Macquarie Park, Australia
  • Sanofi-aventis Administrative Office
    Laval, Canada
  • Sanofi-aventis Administrative Office
    Helsinki, Finland
  • Sanofi-aventis Administrative Office
    Milano, Italy
  • Sanofi-aventis Administrative Office
    Barcelona, Spain
  • Sanofi-aventis Administrative Office
    Bromma, Sweden
  • Sanofi-aventis Administrative Office
    Geneva, Switzerland
08

References and documents

Publications

  • Despres JP, Golay A, Sjostrom L; Rimonabant in Obesity-Lipids Study Group. Effects of rimonabant on metabolic risk factors in overweight patients with dyslipidemia. N Engl J Med. 2005 Nov 17;353(20):2121-34. doi: 10.1056/NEJMoa044537. PubMed 16291982 ↗
09

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Sep 2001, a primary completion of Nov 2003 and a completion of Nov 2003. It does not say whether these dates are actual or estimated.

How these figures are worked out, and which studies are left out of them.

Registered
Jan 23, 2002
First posted
Jan 24, 2002
Start
Sep 2001
Primary completionActual
Nov 2003
CompletionActual
Nov 2003
Last update
Apr 20, 2009
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 20, 2009, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT00029835
Lead sponsor
Sanofi
First posted
Jan 24, 2002
Start date
Sep 2001
Primary completion
Nov 2003
Completion
Nov 2003
Last update
Apr 20, 2009

Study contacts

ICD CSD
study director · Sanofi
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Apr 2009. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Rimonabant

Start the discussion